Everolimus and Mitapivat interaction

Everolimus and Mitapivat: both prescribing labels flag this combination with the strongest language, such as a contraindication, a boxed warning, or an instruction to avoid it.

Major

Do not combine without a prescriber's guidance. The label language below is the strongest FDA uses.

What the FDA labels say

From the Everolimus (Afinitor) label · effective 2026-06-01

Major

Strong CYP3A inhibitor and P-gp inhibitor : Avoid coadministration.

Drug interactionsby drug classView label on DailyMed
Major

Effect of Other Drugs on AFINITOR/AFINITOR DISPERZ Strong or Moderate CYP3A Inhibitor and P-gp Inhibitor Avoid the coadministration of a strong CYP3A inhibitor and P-gp inhibitor [see Dosage and Administration (2.11), Clinical Pharmacology (12.3)] .

Drug interactionsby drug classView label on DailyMed
Moderate

Moderate CYP3A inhibitor and P-gp inhibitor : Reduce the dosage as recommended.

Drug interactionsby drug classView label on DailyMed
Moderate

Strong CYP3A inducer and P-gp inducer : Increase the dosage as recommended.

Drug interactionsby drug classView label on DailyMed
Moderate

Strong CYP3A Inducer and P-gp Inducer Increase the dosage for AFINITOR/AFINITOR DISPERZ with a strong CYP3A inducer and Pg-p inducer as recommended [see Dosage and Administration (2.11), Clinical Pharmacology (12.3)] .

Drug interactionsby drug classView label on DailyMed

From the Mitapivat (AQVESME) label · effective 2026-08-27

Major

Strong CYP3A Inhibitors and Inducers: Avoid concomitant use.

Drug interactionsby drug classView label on DailyMed
Major

Moderate CYP3A Inhibitors: Avoid concomitant use.

Drug interactionsby drug classView label on DailyMed
Major

Prevention or Management Avoid co-administration of strong CYP3A inhibitors with AQVESME [see Dosage and Administration (2.4) ] .

Drug interactionsby drug classView label on DailyMed
Major

Prevention or Management Avoid co-administration of moderate CYP3A inhibitors with AQVESME [see Dosage and Administration (2.4) ] .

Drug interactionsby drug classView label on DailyMed
Moderate

Effect of Other Drugs on AQVESME Strong CYP3A Inhibitors Clinical Impact Co-administration of AQVESME with strong CYP3A inhibitors increased mitapivat plasma concentrations [see Clinical Pharmacology (12.3) ] .

Drug interactionsby drug classView label on DailyMed

Taking more than these two? Interactions stack. Check your whole list at once; it stays in your browser.

Open in the checker

Not medical advice. Interaction Checker quotes FDA label text and NIH fact sheets. Whether an interaction matters for you depends on doses, timing, kidney and liver function, and other conditions. Confirm with a pharmacist or prescriber.